# US 2021/0277066 A1 · Methods and compositions for delivery of agents across the blood-brain barrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277066 A1
- Document ID: US20210277066A1
- Status: Published application
- Kind: A1
- Application number: 17/258,846
- Filed: 2019-07-11
- Published: 2021-09-09
- Earliest claimed: 2018-07-11
- Assignees: The Brigham and Women S Hospital, Inc.
- Applicants: The Brigham and Women`s Hospital, Inc.
- Inventors: Fengfeng Bei
- Web page: https://patentgrep.com/patent/US20210277066A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 35/761: Adenovirus
- A61K 38/45: Transferases (2)
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 49/0045: {the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo}
- A61K 49/0097: {Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo}
- A61P 35/00: Antineoplastic agents
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C07K 2319/00: Fusion polypeptide
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is based on the development of artificial targeting sequences that enhance permeation of agents into cells and across the blood brain barrier, compositions comprising the sequences, and methods of use thereof. Provided herein is an AAV comprising a capsid protein comprising a targeting sequence and a transgene, preferably a therapeutic or diagnostic transgene. Further, provided herein are methods of delivering a transgene to a cell, the method comprising contacting the cell with an AAV or fusion protein described herein.

## Claims

### Claim 1

An AAV capsid protein comprising an amino acid sequence that comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO:8); TVSALK (SEQ ID NO:4); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).

### Claim 2 (depends on 1)

The AAV capsid protein of claim 1, comprising an amino acid sequence that comprises at least five contiguous amino acids from the sequence TVSALK (SEQ ID NO:4); TVSALFK (SEQ ID NO:8); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).

### Claim 3 (depends on 1)

The AAV capsid protein of claim 1, comprising an amino acid sequence that comprises at least six contiguous amino acids from the sequence TVSALK (SEQ ID NO:4); TVSALFK (SEQ ID NO:8); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).

### Claim 4 (depends on 1)

The AAV capsid protein of claim 1, wherein the AAV is AAV9.

### Claim 5 (depends on 1)

The AAV capsid protein of claim 1, comprising AAV9 VP1.

### Claim 6 (depends on 5)

The AAV capsid protein of claim 5, wherein the targeting sequence is inserted in a position corresponding to amino acids 588 and 589 of SEQ ID NO:85.

### Claim 7 (depends on 1)

A nucleic acid encoding the AAV capsid protein of claim 1.

### Claim 8 (depends on 1)

An AAV comprising the capsid protein of claim 1.

### Claim 9 (depends on 8)

The AAV of claim 8, further comprising a transgene, preferably a therapeutic transgene.

### Claim 10

A targeting sequence comprising V[S/p][A/m/t/]L (SEQ ID NO:79), TV[S/p][A/m/t/]L (SEQ ID NO:80), TV[S/p][A/m/t/]LK (SEQ ID NO:81), or TV[S/p][A/m/t/]LFK. (SEQ ID NO:82).

### Claim 11 (depends on 10)

The targeting sequence of claim 10, wherein the targeting sequence comprises VPALR (SEQ ID NO:1); VSALK (SEQ ID NO:2); TVPALR (SEQ ID NO:3); TVSALK (SEQ ID NO:4); TVPMLK (SEQ ID NO:12); TVPTLK (SEQ ID NO:13); FTVSALK (SEQ ID NO:5); LTVSALK (SEQ ID NO:6); TVSALFK (SEQ ID NO:8); TVPALFR (SEQ ID NO:9); TVPMLFK (SEQ ID NO:10) or TVPTLFK (SEQ ID NO:11).

### Claim 12 (depends on 10)

A fusion protein comprising the targeting sequence of claim 10, and a heterologous sequence.

### Claim 13 (depends on 10)

An AAV capsid protein comprising the targeting sequence of claim 10.

### Claim 14 (depends on 13)

The AAV capsid protein of claim 13, comprising AAV9 VP1.

### Claim 15 (depends on 14)

The AAV capsid protein of claim 14, wherein the targeting sequence is inserted in a position corresponding to amino acids 588 and 589 of SEQ ID NO.

### Claim 16 (depends on 10)

A nucleic acid encoding the targeting sequence, fusion protein or AAV capsid protein of claim 10.

### Claim 17 (depends on 13)

An AAV comprising the capsid protein of claim 13.

### Claim 18 (depends on 17)

The AAV of claim 17, further comprising a transgene, preferably a therapeutic transgene.

### Claim 19 (depends on 1)

A method of delivering a transgene to a cell, the method comprising contacting the cell with the AAV of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cell is a neuron (optionally a dorsal root ganglion neuron), astrocyte, cardiomyocyte, or myocyte.

### Claim 21 (depends on 19)

The method of claim 19, wherein the cell is in a living subject.

### Claim 22 (depends on 19)

The method of claim 19, wherein the subject is a mammalian subject.

### Claim 23 (depends on 20)

The method of claim 20, wherein the cell is in a tissue selected from the brain, spinal cord, dorsal root ganglion, heart, or muscle, and a combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the subject has a neurodegenerative disease, epilepsy; stroke; spinocerebellar ataxia; Canavan's disease; Metachromatic leukodystrophy; Spinal muscular atrophy; Friedreich's ataxia; X-linked centronuclear myopathy; Lysosomal storage disease; Barth syndrome; Duchenne muscular dystrophy; Wilson's disease; or Crigler-Najjar syndrome type 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the neurodegenerative disease is Parkinson's disease; Alzheimer's disease; Huntington's disease; Amyotrophic lateral sclerosis; and Multiple sclerosis.

### Claim 26 (depends on 23)

The method of claim 23, wherein the subject has a brain cancer, and the method includes administering an AAV encoding an anti-cancer agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein the anti-cancer agent is HSV.TK1, and the method further comprises administering ganciclovir.

### Claim 28 (depends on 22)

The method of claim 22, wherein the cell is in the brain of the subject, and the AAV is administered by parenteral delivery; intracerebral; or intrathecal delivery.

### Claim 29 (depends on 28)

The method of claim 28, wherein the parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.

### Claim 30 (depends on 28)

The method of claim 28, wherein the intrathecal delivery is via lumbar injection, cisternal magna injection, or intraparenchymal injection.
